Atopic Dermatitis Market by Product (Corticosteroids, Emollients/Moisturizers, IL-4 & PDE4 Inhibitors, Calcineurin Inhibitors Antibiotics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2022-2031

The Atopic Dermatitis market was valued at $7.4 billion in 2022. It is projected to grow at a CAGR of 23.8% from 2023 to 2031 and reach more than $58.7 billion by the end of 2031. 

Analysts’ Viewpoint by Cognate Lifesciences

According to industry analysts, the global atopic dermatitis market is expected to see significant growth in the coming years, driven increasing prevalence and awareness of this chronic inflammatory skin condition, is poised for substantial growth.

Innovations in treatment modalities, including biologics and targeted therapies, are expected to reshape the therapeutic landscape for AD. The growing emphasis on personalized medicine and the development of novel pharmaceuticals underscore a promising future for patients grappling with the often debilitating symptoms of this skin disorder. Analysts anticipate a surge in research and development activities, collaborations, and strategic partnerships within the pharmaceutical industry to address unmet needs in AD management. Additionally, factors such as improved healthcare infrastructure, rising healthcare expenditures, and a proactive approach to skin health further contribute to the positive outlook for the AD market. While challenges persist, the collective efforts of researchers, healthcare providers, and pharmaceutical companies are likely to pave the way for innovative treatments, ultimately improving the quality of life for individuals affected by Atopic Dermatitis.

Atopic Dermatitis Overview 

Atopic dermatitis, a persistent condition, induces skin inflammation, leading to manifestations like redness, itching, swelling, and skin fissures. The affected region may exhibit a discharge of white fluid, necessitating intervention. Typically initiating in childhood, atopic dermatitis can intensify over time. The origins of this condition are rooted in a combination of genetic factors, environmental influences, immune system irregularities, and challenges related to skin permeability.

The market for atopic dermatitis is poised for substantial growth in the foreseeable future, primarily attributed to the swift advancement of novel pipeline drugs that is set to propel the atopic dermatitis market size. Concurrently, the increasing demand for innovative biologics, along with a surge in product approvals and a growing number of participants in the atopic dermatitis industry, is expected to further augment market expansion. Favorable reimbursement policies in emerging economies, coupled with a high prevalence of atopic dermatitis, are additional factors foreseen to drive the growth rate of the market. Additionally, heightened awareness about the availability of treatments, government initiatives to enhance accessibility to affordable treatments, and the continuous technological progress, supported by increased funding and government backing for research and development, are poised to generate new opportunities, thereby influencing the global atopic dermatitis market share in the forecast period.

Nevertheless, the ready accessibility of costly treatments and inadequate reimbursement policies in developing regions worldwide are anticipated to serve as significant impediments to the expansion of the atopic dermatitis market. Additionally, the allergic reactions associated with off-label therapies and the expiration of product patents pose challenges to the growth trajectory of the target market during the aforementioned forecast period for atopic dermatitis.

New product launches to flourish in the market

The atopic dermatitis market is expected to see several new product launches in the coming years. Some of the key product launches expected in the atopic dermatitis market are:

• Mitchga Subcutaneous Injection – In August 2022, Chugai Pharmaceutical Co., Ltd., in collaboration with Maruho Co., Ltd., revealed the introduction of Mitchga Subcutaneous Injection, an anti-IL-31 receptor A humanized monoclonal antibody designed to address itching linked with atopic dermatitis. The Ministry of Health, Labour and Welfare (MHLW) granted approval for Mitchga on March 28, 2022.
• Atopic Dermatitis Hub - In June 2022, Otsuka's launch of Moizerto Ointment a new treatment for atopic dermatitis in Japan. The introduction of Moizerto broadened the range of available treatments for atopic dermatitis, potentially leading to better outcomes for patients with different needs and preferences.

Segment Overview:

By Drug Type: The atopic dermatitis market is divided into corticosteroids, emollients/moisturizers, il-4 & pde4 inhibitors, calcineurin inhibitors antibiotics, and others. The dominating segment of the Atopic Dermatitis market is corticosteroids. This segment is expected to account for the largest share of the market in the coming years. Corticosteroids have been used for decades to treat atopic dermatitis, and their effectiveness in reducing inflammation and itching is well documented. Their track record of success has made them a trusted and reliable option for both healthcare professionals and patients. Corticosteroids provide rapid relief from the itching and inflammation associated with atopic dermatitis. This immediate relief can significantly improve patients' quality of life and make it easier to manage their symptoms. While corticosteroids currently lead the market, the landscape is evolving. The emergence of newer, targeted therapies like il-4 & pde4 inhibitors is gaining momentum due to their potential for fewer side effects and a more precise approach to managing atopic dermatitis. However, corticosteroids are likely to remain a mainstay treatment for the foreseeable future due to their established efficacy, affordability, and familiarity.

By Distribution Channel: The Atopic Dermatitis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to dominate the atopic dermatitis market in the coming years. Often, patients with severe or complicated atopic dermatitis require specialist care and treatment, making hospital pharmacies their primary source of medication. Certain atopic dermatitis drugs, like biologics, require specific handling and storage, which hospital pharmacies are equipped to provide. The atopic dermatitis market is dynamic and constantly evolving. While currently dominated by hospital pharmacies, the rapid growth of online platforms and the continued presence of retail pharmacies present a fascinating landscape for the future of medication distribution in this sector.

By Region:

The North American region is projected to maintain its dominance in the global atopic dermatitis market. In North America, the atopic dermatitis market commands the largest share, constituting approximately 36% of the global market. This dominance can be attributed to several factors, including the region's high prevalence of atopic dermatitis, advanced healthcare infrastructure, and the robust presence of pharmaceutical companies. Within the market segments, corticosteroids and biologics emerge as dominant categories, each holding significant shares. Corticosteroids maintain their prominence due to established efficacy in managing atopic dermatitis, while biologics have witnessed recent advancements, contributing to their substantial market presence. The dynamic landscape in North America reflects a blend of traditional therapeutic approaches and cutting-edge innovations, positioning the region as a key player in addressing the complexities of atopic dermatitis.

The Asia Pacific region stands out as the fastest-growing market for atopic dermatitis, with a projected CAGR of approximately 24%. This remarkable growth is fueled by factors such as the region's substantial and expanding population, increasing disposable income, and the ongoing trend of urbanization. Within this dynamic landscape, specific market dynamics are observed in key emerging markets, including China, India, and Japan. Each of these countries contributes significantly to the regional market, with distinct needs and preferences shaping the atopic dermatitis segment.

As for market segments, emollients and corticosteroids are expected to maintain their dominance in the near term, reflecting established therapeutic approaches. However, a notable trend is the growing traction of biologics and other targeted therapies. The increasing adoption of these innovative treatment modalities signals a shift in the atopic dermatitis landscape in the Asia Pacific region, aligning with a broader global trend towards personalized and advanced healthcare solutions. As the region continues to witness economic and demographic transformations, the atopic dermatitis market in Asia Pacific is poised for substantial evolution, offering opportunities for diverse therapeutic interventions to cater to the specific needs of its diverse population.

Competitive analysis and profiles of the major players in the atopic dermatitis market, such as Galderma, Pfizer Inc, Regeneron Pharmaceuticals, Inc, LEO Pharma A/S, Sanofi, Novartis AG, Bristol-Myers Squibb Company, Bayer AG, Bausch Health, Allergan, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, AbbVie Inc., Encore Dermatology, Inc., Astellas Pharma Inc., Mylan N.V., AstraZeneca, 3M, and Teva Pharmaceutical Industries Ltd. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the Atopic Dermatitis market. 

Market Scope and Structure Analysis

Key Segments Covered

Drug Type

• Corticosteroids
• Emollients/Moisturizers
• IL-4 & PDE4 Inhibitors
• Calcineurin Inhibitors Antibiotics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Israel
  • Rest of Middle East & Africa